Minerva Neurosciences

Minerva Neurosciences FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Minerva Neurosciences (NERV) as of Nov 5, 2026 is 4,604.59 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -1,358.75 % — a change of -438.88% (higher).

FCF Conversion

4,604.59 %

YoY

-438.88%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Minerva Neurosciences is 2025 4,604.59 % . FCF Conversion Rate (FCF/EBITDA) of Minerva Neurosciences was 2024 -1,358.75 % . It decreases by -438.88% higher compared to the previous year.

The Minerva Neurosciences FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
83.60 USD
Jan 1, 2019
60.17 USD
Jan 1, 2020
-1,743.35 USD
Jan 1, 2021
49.33 USD
Jan 1, 2022
76.81 USD
Jan 1, 2023
49.27 USD
Jan 1, 2024
-1,358.75 USD
Jan 1, 2025
4,604.59 USD
The Minerva Neurosciences FCF Conversion history
YEARFCF ConversionYoY
4,604.59 %-438.88%
-1,358.75 %-2,857.56%
49.27 %-35.85%
76.81 %+55.70%
49.33 %-102.83%
-1,743.35 %-2,997.39%
60.17 %-28.02%
83.60 %-966.73%
-9.65 %-111.63%
82.91 %-7.68%
89.81 %+41.92%
63.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Minerva Neurosciences Stock analysis

What does Minerva Neurosciences do? Minerva Neurosciences Inc, based in Waltham, US, is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases. The company, listed in 2014, operates with a portfolio including MIN-101 for schizophrenia, MIN-202 for insomnia and depression, MIN-117 for depression, and MIN-301 for Parkinson's disease. It employs seven full-time staff and targets neurological conditions through innovative biotechnology approaches. Minerva Neurosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Minerva Neurosciences stock

FCF Conversion Rate (FCF/EBITDA) of Minerva Neurosciences is 4,604.59 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Minerva Neurosciences changed from -1,358.75 % to 4,604.59 %, representing a -438.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Minerva Neurosciences since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Minerva Neurosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Minerva Neurosciences

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Minerva Neurosciences